Flashpoint Therapeutics Announces Publication Demonstrating Superior Pre-Clinical Anti-Leukemia Efficacy with its Structural Nanomedicine Platform
Flashpoint Therapeutics Announces Major Publication Supporting Application of its Proprietary Structural Nanomedicine Platform to CRISPR-based Therapeutics
Flashpoint Therapeutics Scientific Founder, Chad Mirkin, Receives 2024 Kavli Prize for Groundbreaking Work on Spherical Nucleic Acids